静脉血栓栓塞症危险因素课件.pptVIP

美国每年至少2百万新发VTE，其中1/10的患者死亡 * Figure 1. Results of Trials of Prophylaxis for Venous Thromboembolism in High-Risk Hospitalized Patients. In three randomized, double-blind trials, enoxaparin, dalteparin, or fondaparinux was compared with placebo for the prevention of venous thromboembolism. The use of the anticoagulant resulted in significantly decreased rates of thromboembolism in the Prophylaxis in Medical Patients with Enoxaparin (MEDENOX) trial (P0.001),7 the Prospective Evaluation of Dalteparin Efficacy for Prevention of VTE in Immobilized Patients Trial (PREVENT) (P = 0.002),8 and the Arixt